4.295

1.74% -0.075

Adc Therapeutics Sa (ADCT)

Overview News Price History Option Chain Discussions Forecast

Adc Therapeutics Sa stock is traded at $4.295, with a volume of 235.73K. It is down -1.74% in the last 24 hours and up +4.99% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Previous Close:

$4.37

Open:

$4.39

24h Volume:

235.73K

Relative Volume:

0.27

Market Cap:

$531.43M

Revenue:

$69.56M

Net Income/Loss:

$-240.05M

P/E Ratio:

-1.4559

EPS:

-2.95

Net Cash Flow:

$-121.90M

1W Performance:

+7.35%

1M Performance:

+4.99%

6M Performance:

+76.71%

1Y Performance:

+111.53%

1-Day Range:

$4.21

$4.44

1-Week Range:

$3.9218

$4.44

52-Week Range:

$1.05

$4.80

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name

Adc Therapeutics Sa

Sector

Healthcare (1138)

Industry

Biotechnology (635)

Phone

41 21 653 02 00

Address

BIOPOLE, EPALINGES

Employee

263

Twitter

Next Earnings Date

2025-03-21

Latest SEC Filings

ADCT's Discussions on Twitter

Compare ADCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADCT Adc Therapeutics Sa	4.29	541.34M	69.56M	-240.05M	-121.90M	-2.95
VRTX Vertex Pharmaceuticals Inc	429.20	107.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	781.88	80.03B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	431.18	57.37B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	908.04	55.83B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	207.44	44.13B	447.02M	-1.18B	-906.14M	-6.1812

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-06-22	Initiated	CapitalOne	Overweight
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-21	Initiated	Wolfe Research	Outperform
Aug-17-21	Resumed	Jefferies	Buy
Aug-09-21	Initiated	RBC Capital Mkts	Outperform
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight
Dec-03-20	Initiated	Stifel	Hold
Oct-29-20	Initiated	H.C. Wainwright	Buy
Jun-09-20	Initiated	BofA/Merrill	Buy
Jun-09-20	Initiated	Cowen	Outperform

View All

Adc Therapeutics Sa Stock (ADCT) Latest News

Nov 24, 2025

ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 24, 2025

Nov 20, 2025

How ADC Therapeutics SA Common Shares stock expands through international markets2025 Momentum Check & Expert Curated Trade Setup Alerts - newser.com

Nov 20, 2025

How cyclical is ADC Therapeutics SA Common Shares stock compared to rivalsJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com

Nov 20, 2025

Can ADC Therapeutics SA stock attract ESG capital inflowsMarket Sentiment Report & Weekly Sector Rotation Insights - newser.com

Nov 20, 2025

Nov 19, 2025

Should I buy ADC Therapeutics SA Common Shares stock before earnings season2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - newser.com

Nov 19, 2025

Chart overlay techniques for tracking ADC Therapeutics SAQuarterly Portfolio Review & High Accuracy Swing Trade Signals - newser.com

Nov 19, 2025

Will ADC Therapeutics SA Common Shares stock draw ESG focused fundsJuly 2025 Reactions & Daily Profit Focused Stock Screening - newser.com

Nov 19, 2025

Adc Therapeutics at Jefferies Conference: Strategic Expansion Plans By Investing.com - Investing.com UK

Nov 19, 2025

What indicators show strength in ADC Therapeutics SAJuly 2025 Snapshot & Consistent Income Trade Recommendations - newser.com

Nov 19, 2025

Nov 18, 2025

Will ADC Therapeutics SA Common Shares stock beat Nasdaq index returnsEarnings Risk Summary & Expert Curated Trade Ideas - newser.com

Nov 18, 2025

Is ADC Therapeutics SA stock a defensive play in 20252025 Retail Activity & Fast Gain Swing Trade Alerts - newser.com

Nov 18, 2025

ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know - sharewise.com

Nov 18, 2025

Nov 17, 2025

Will ADC Therapeutics SA stock deliver long term returnsJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com

Nov 17, 2025

Nov 16, 2025

ADC Therapeutics (ADCT) Secures PIPE Financing, Price Target Adjusted - MSN

Nov 16, 2025

Is ADC Therapeutics SA stock bottoming outJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - newser.com

Nov 16, 2025

How to track smart money flows in ADC Therapeutics SAWeekly Stock Summary & High Accuracy Investment Entry Signals - newser.com

Nov 16, 2025

Wall Street Zen Upgrades ADC Therapeutics (NYSE:ADCT) to "Hold" - MarketBeat

Nov 16, 2025

Nov 15, 2025

Is it time to cut losses on ADC Therapeutics SACPI Data & Low Volatility Stock Recommendations - newser.com

Nov 15, 2025

Is ADC Therapeutics SA stock a top pick in earnings seasonQuarterly Profit Review & Community Driven Trade Alerts - newser.com

Nov 15, 2025

Why analysts upgrade ADC Therapeutics SA stockEarnings Overview Summary & Real-Time Market Sentiment Reports - newser.com

Nov 15, 2025

How institutional ownership impacts ADC Therapeutics SA stockTreasury Yields & Fast Gaining Stock Reports - newser.com

Nov 15, 2025

Nov 14, 2025

ADC Therapeutics SA Common Shares (NY: ADCT - Markets Financial Content

Nov 14, 2025

FY2025 EPS Estimates for ADCT Increased by Cantor Fitzgerald - MarketBeat

Nov 14, 2025